SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial
11 references·2 citing·35 second hop
An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial (2005)An economic evaluation of Herceptin® in a…A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis (2005)A monoclonal antibody against…Discounting Health Outcomes in Economic Evaluation: The Ongoing Debate (2004)Discounting Health Outcomes i…What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)What Is the Price of Life and…NICE: faster access to modern treatments? Analysis of guidance on health technologies (2001)NICE: faster access to modern…Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Health Economic Guidelines—Si…Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer (2000)Estimates of the Lifetime Dir…Early Modelling for Assessing Health and Economic Outcomes of Drug Therapy (2000)Early Modelling for Assessing…Handling uncertainty when performing economic evaluation of healthcare interventions. (1999)Handling uncertainty when per…Quality of Life and Pharmacoeconomics: An Introduction (1998)Quality of Life and Pharmacoe…Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel …The Distinction Between Cost and Charges (1982)The Distinction Between Cost …Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium (2008)Trastuzumab in early stage br…Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis (2006)Trastuzumab in adjuvant breas…EuroQol - a new facility for the measurement of health-related quality of life (1990)Cost-Effectiveness in Health and Medicine (1996)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: Cost effectiveness (2000)Modelling in the economic evaluation of health care: selecting the appropriate approach (2004)Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation (2006)Protected Values and Omission Bias (1999)Willingness to Pay for a Quality-adjusted Life Year (2000)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities (2009)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors (2018)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)Recommendations for Reporting Cost-effectiveness Analyses (1996)Criteria for evaluating evidence on public health interventions (2002)Methods for the Economic Evaluation of Health Care Programmes (2005)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Methods for the economic evaluation of health care programmes (1987)Health outcomes in economic evaluation: the QALY and utilities (2010)The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model (2012)Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (2018)Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care (1995)The economic burden of metastatic breast cancer: a U.S. managed care perspective (2012)Indirect costs associated with metastatic breast cancer (2013)Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)The Delphi technique: a comparison of results obtained using two expert panels (1993)Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis (1994)Early-Stage Valuation of Medical Devices: The Role of Developmental Uncertainty (2010)A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme (2004)The cost-effectiveness of screening for oral cancer in primary care (2006)Clinical Economics (1989)A Clinician's Guide to Cost-Effectiveness Analysis (1990)Cost of Care for Elderly Cancer Patients in the United States (2008)Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health (2005)Using Value of Information Analysis to Prioritise Health Research (2006)Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias (2009)
this work references cited by second hop

References

  • 1996Recommendations of the Panel on Cost-Effectiveness in Health and Medicine2,507 cited
  • 1982The Distinction Between Cost and Charges1,055 cited
  • 2003What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?588 cited
  • 1999Handling uncertainty when performing economic evaluation of healthcare interventions.387 cited
  • 2001Health Economic Guidelines—Similarities, Differences and Some Implications322 cited
  • 2001NICE: faster access to modern treatments? Analysis of guidance on health technologies299 cited
  • 2004Discounting Health Outcomes in Economic Evaluation: The Ongoing Debate179 cited
  • 1998Quality of Life and Pharmacoeconomics: An Introduction77 cited
  • 2000Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer60 cited
  • 2000Early Modelling for Assessing Health and Economic Outcomes of Drug Therapy59 cited
  • 2005A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis58 cited

Cited by

  • 2008Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium51 cited
  • 2006Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis48 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work